Femasys Inc Ordinary Shares FEMY 深 滬
等待開盤 11-26 09:30:00 美东时间
0.9907
+0.072
+7.78%
華盛通- 最 高1.04
- 今 開0.9162
- 成交量 298.80万股
- 最 低 0.9129
- 昨 收 0.9192
- 總市值 4261.00万
- 52周最高 1.80
- 市盈率 靜 --
- 換手率 6.95%
- 52周最低 0.3067
- 委 比 92.59%
- 總股本 4301.00万
- 歷史最高 13.75
- 量 比 1.12
- 振 幅 13.83%
- 歷史最低 0.2479
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
Laidlaw & Co. Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $6.5
Laidlaw & Co. analyst Yale Jen initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating and announces Price Target of $6.5.
11-20 22:44
Femasys shares are trading higher after the company announced FDA clearance to continue enrollment in the final phase of its FINALE trial for FemBloc and entered agreements to issue $12M in notes and warrants, potentially raising up to $58M.
Femasys shares are trading higher after the company announced FDA clearance to ...
11-03 21:35
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
Biomedical innovator Femasys Inc. announced the commencement of a post-market surveillance (PMS) clinical study for its CE-marked FemBloc Permanent Birth Control, aligning with the European Union Medical Device Regulation (MDR 2017/745). The study, approved by multiple Ethics Committees and conducted in compliance with ISO 14155:2020, aims to monitor safety and performance in real-world settings. FemBloc, a first-of-its-kind non-surgical solution...
10-22 13:00
Femasys Meets Nasdaq Equity Requirement After Offering
Femasys ( ($FEMY) ) has issued an update. On May 19, 2025, Femasys Inc. receive...
10-21 21:48
Femasys COO Daniel Currie Announces Retirement
Femasys ( ($FEMY) ) has provided an announcement. On October 13, 2025, Daniel C...
10-18 05:50
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
Femasys Inc. will showcase its latest fertility solution, FemaSeed® Intratubal Insemination, at the ASRM 2025 Scientific Congress & Expo in San Antonio, Texas. The product, designed to enhance natural fertilization by delivering sperm to the fallopian tube, offers a safe, accessible, and cost-effective alternative to intrauterine insemination (IUI). With more than double the pregnancy rates of IUI in cases of low male sperm count, FemaSeed is aut...
10-16 13:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 46.4% to $0.37 during Tuesday...
10-15 05:06
Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) rose sharply in pre-market ...
10-06 21:01
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
<p>Femasys Inc. has partnered with Kebomed to commercialize its FemBloc permanent birth control in France and the Benelux region, leveraging Kebomed’s extensive European distribution network. FemBloc, a first-of-its-kind non-surgical solution for permanent contraception, addresses unmet needs in women’s reproductive health by eliminating risks associated with surgical sterilization. This collaboration marks a significant step in Femasys’ European...
09-25 13:00
